Health and Wellness
It will focus on creating digital solutions for ophthalmic, neurological and psychiatric disorders.
Cue received emergency use authorization for its at-home COVID-19 test in March and went public in September.
The tool uses information about pain level, condition and current medication regimen to find an effective dose of opioids.
Also: Pediatric sleep app Huckleberry raises $12.5 million, and illumigyn, maker of a platform for remote gynecological imaging, brings in $33 million.
The device will sell for $69.99 and ship in December.
The company said its valuation is now $1.4 billion.
The latest round follows a $14 million Series B raise from 2019.
The company said the Series B brings its total raise to $20 million.
The internet cognitive behavioural therapy programme will launch in 2022.
The POGO system was first cleared by the FDA in 2016.